Enterprise Value

7.369B

Cash

463.5M

Avg Qtr Burn

N/A

Short % of Float

6.80%

Insider Ownership

1.11%

Institutional Own.

99.21%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TLANDO Details
TRT (Testosterone Replacement Therapy)

Approved

Update

Approved

Quarterly sales

DARZALEX (daratumumab) Details
MM (Multiple myeloma)

Approved

Quarterly sales

Approved

Quarterly sales

Otrexup (Methotrexate) Details
RA (rheumatoid arthritis) and psoriasis

Approved

Quarterly sales

Approved

Quarterly sales

PDUFA

Approval decision

Phase 3

Data readout

Phase 3

Update